HOLLISTON, Mass., August 8, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the second quarter ended June 30, 2024.

Jim Green, Chairman and CEO, said, “Second quarter revenues reflect a more challenging than expected market environment. With the uncertainty of the timing for market recovery we stayed focused on managing costs and the actions we implemented during Q2 are expected to drive annualized savings of approximately $4 million while we continue our work on new product development and growth initiatives.”

Green continued, “We believe the market recovery is likely delayed to later in the second half however we remain excited about the long-term growth prospects from our innovative new products.”

This press release includes certain financial information presented on an adjusted, or non-GAAP, basis. For additional information on the non-GAAP financial measures included in this press release, please see “Use of Non-GAAP Financial Information” and “Reconciliation of GAAP to Non-GAAP Financial Measures” below.

For the second quarter of fiscal 2024, the Company reported revenues of $23.1 million compared to $28.8 million in the second quarter of fiscal 2023. Gross margin for the three months ended June 30, 2024 was 57.2% compared with 58.0% in the comparable quarter of the prior year. Gross profit was $13.2 million for the second quarter of 2024 compared to $16.7 million in the same period last year. Gross margin below the Company’s target of 60% was primarily due to lower absorption of fixed manufacturing costs.

Net loss for the second quarter of 2024 was $(2.9) million compared to a net loss of $(1.0) million in the second quarter of 2023, which included a loss on marketable securities of ($0.3) million and $(1.6) million in 2024 and 2023, respectively. Net loss was primarily impacted by the dropdown impact of lower revenues. Adjusted EBITDA for the second quarter of 2024 was $1.3 million, compared to $3.9 million in the second quarter of the prior year.

For the six months ended June 30, 2024, revenues were $47.6 million, compared to $58.7 million in the same period a year ago. Gross margin for the six months ended June 30, 2024 was 58.8% compared with 59.6% in the comparable period of the prior year. Gross profit was $28.0 million for the first half of 2024 compared to $35.0 million in the same period last year. The reduction in gross margin below the Company’s target of 60% was primarily due to lower absorption of fixed manufacturing costs.

Net loss for the six months ended June 30, 2024 was ($7.6) million compared to a net loss of $(0.4) million in the same period of 2023, primarily due to the dropdown impact of lower revenues. Adjusted EBITDA for the six months ended June 30, 2024 was $2.9 million, compared to adjusted EBITDA of $8.7 million for the comparable period of 2023.

Cash provided by operations was $0.6 million during the six months ended June 30, 2024 compared to $5.4 million in the same period last year.

In light of a delayed market recovery, the Company is reducing its full year 2024 revenue outlook to approximately $97 million to $102 million. The Company expects 2024 full year gross margin of approximately 59% to 60% and adjusted EBITDA margin in the high single digits.

In conjunction with this announcement, Harvard Bioscience will be hosting a conference call and webcast today at 10:00 a.m. Eastern Time. A presentation that will be referenced during the webcast will be posted to the Company’s Investor Relations website shortly before the webcast begins.

Analysts who would like to join the call and ask a question must register here (https://edge.media-server.com/mmc/p/d3g5cbbp). Once registered, you will receive the dial-in numbers and a unique PIN number.

Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here (https://investor.harvardbioscience.com/events-and-presentations).

In this press release, we have included non-GAAP financial information, including one or more of adjusted operating income (loss), adjusted operating margin, adjusted net income (loss), adjusted EBITDA, adjusted EBITDA margin, diluted adjusted earnings (loss) per share, and net debt. We believe that this non-GAAP financial information provides investors with an enhanced understanding of the underlying operations of the business. For the periods presented, these non-GAAP financial measures have excluded certain expenses and income resulting from items that we do not believe are representative of the underlying operations of the business. Items excluded include stock-based compensation, amortization of intangibles related to acquisitions, other operating expenses, loss on equity securities, income taxes, and the tax impact of the reconciling items. Management believes that this non-GAAP financial information is important in comparing current results with prior period results and is useful to investors and financial analysts in assessing the Company’s operating performance.

Non-GAAP historical financial statement information included herein is accompanied by a reconciliation to the nearest corresponding GAAP measure which is included as exhibits below in this press release.

With respect to non-GAAP forward-looking measures, we provide an outlook for adjusted EBITDA margin. Many of the items that we exclude from this forward-looking measure calculation are less capable of being controlled or reliably predicted by management. These items could cause the forward-looking measures presented in our outlook statements to vary materially from our GAAP results.

The non-GAAP financial information provided in this press release should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP and may be different than other companies’ non-GAAP financial information.

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions or statements that do not relate to historical matters. Forward-looking statements include, but are not limited to, information concerning expected future financial and operational performance including revenues, gross margins, earnings, cash and debt position, growth and the introduction of new products, the strength of the Company’s market position and business model and anticipated macroeconomic conditions. Forward-looking statements are not guarantees of future performance and involve known and unknown uncertainties, risks, assumptions, and contingencies, many of which are outside the Company’s control. Risks and other factors that could cause the Company’s actual results to differ materially from those described its forward-looking statements include those described in the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K as well as in the Company’s other filings with the Securities and Exchange Commission. Forward-looking statements are based on the Company’s expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to reflect any change in expectations, even as new information becomes available.

HARVARD BIOSCIENCE, INC.

Consolidated Statements of Operations

(unaudited, in thousands, except per share data)

	Three Months Ended						Six Months Ended
	June 30, 2024			June 30, 2023			June 30, 2024			June 30, 2023

Revenues	$	23,097		$	28,759		$	47,609		$	58,734
Cost of revenues		9,879			12,086			19,619			23,715
Gross profit		13,218			16,673			27,990			35,019

Operating expenses:
Sales and marketing expenses		5,395			6,178			11,299			12,156
General and administrative expenses		5,686			5,353			11,649			11,687
Research and development expenses		2,626			2,957			5,511			5,854
Amortization of intangible assets		1,331			1,389			2,664			2,777
Other operating expenses		249			-			1,215			-
Total operating expenses		15,287			15,877			32,338			32,474

Operating (loss) income		(2,069	)		796			(4,348	)		2,545

Other income (expense):
Interest expense		(749	)		(941	)		(1,500	)		(1,915	)
Loss on equity securities		(281	)		(1,581	)		(1,593	)		(1,581	)
Other (expense) income, net		(181	)		(372	)		(323	)		60
Total other expense		(1,211	)		(2,894	)		(3,416	)		(3,436	)
Loss before income taxes		(3,280	)		(2,098	)		(7,764	)		(891	)
Income tax benefit		(353	)		(1,118	)		(143	)		(533	)
Net loss	$	(2,927	)	$	(980	)	$	(7,621	)	$	(358	)

Loss per common share:
Basic and diluted	$	(0.07	)	$	(0.02	)	$	(0.18	)	$	(0.01	)

Weighted-average common shares:
Basic and diluted		43,486			42,354			43,443			42,204

HARVARD BIOSCIENCE, INC.

Condensed Consolidated Balance Sheets

(unaudited, in thousands)

	June 30, 2024		December 31, 2023
Assets
Cash and cash equivalents	$	4,048	$	4,283
Accounts receivable, net		12,486		16,099
Inventories		25,130		24,716
Other current assets		4,766		3,940
Total current assets		46,430		49,038
Property, plant and equipment		4,758		3,981
Goodwill and other intangibles		70,068		73,101
Other long-term assets		7,656		11,246
Total assets	$	128,912	$	137,366

Liabilities and Stockholders' Equity
Current portion, long-term debt	$	3,720	$	5,859
Other current liabilities		18,901		20,683
Total current liabilities		22,621		26,542
Long-term debt, net		31,960		30,704
Other long-term liabilities		7,084		7,046
Stockholders’ equity		67,247		73,074
Total liabilities and stockholders’ equity	$	128,912	$	137,366

HARVARD BIOSCIENCE, INC.

Condensed Consolidated Statements of Cash Flows

(unaudited, in thousands)

	Six Months Ended
	June 30, 2024			June 30, 2023
Cash flows from operating activities:
Net loss	$	(7,621	)	$	(358	)
Adjustments to operating cash flows		8,048			7,101
Changes in operating assets and liabilities		130			(1,379	)
Net cash provided by operating activities		557			5,364

Cash flows from investing activities:
Additions to property, plant and equipment		(1,463	)		(741	)
Acquisition of intangible assets		(223	)		(108	)
Proceeds from sale of product line		-			512
Proceeds from sale of marketable equity securities		1,919			-
Net cash provided by (used in) investing activities		233			(337	)

Cash flows from financing activities:
Borrowing from revolving line of credit		5,550			2,500
Repayment of revolving line of credit		(2,550	)		(5,450	)
Repayment of term debt		(4,023	)		(2,591	)
Proceeds from exercise of employee stock options and purchases		204			724
Taxes paid related to net share settlement of equity awards		(59	)		(451	)
Net cash used in financing activities		(878	)		(5,268	)

Effect of exchange rate changes on cash and cash equivalents		(147	)		57
Decrease in cash and cash equivalents		(235	)		(184	)
Cash and cash equivalents at the beginning of period		4,283			4,508
Cash and cash equivalents at the end of period	$	4,048		$	4,324

HARVARD BIOSCIENCE, INC.

Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)

(in thousands, except per share data and percentages)

	Three Months Ended						Six Months Ended
	June 30, 2024			June 30, 2023			June 30, 2024			June 30, 2023

GAAP operating (loss) income	$	(2,069	)	$	796		$	(4,348	)	$	2,545
Stock-based compensation		1,278			1,102			2,326			2,255
Acquired asset depreciation & amortization		1,338			1,398			2,676			2,798
Other operating expenses (1)		271			-			1,335			-
Other adjustments		-			276			-			408
Adjusted operating income	$	818		$	3,572		$	1,989		$	8,006

Operating margin		(9.0	%)		2.8	%		(9.1	%)		4.3	%
Adjusted operating margin		3.5	%		12.4	%		4.2	%		13.6	%


GAAP net loss	$	(2,927	)	$	(980	)	$	(7,621	)	$	(358	)
Stock-based compensation		1,278			1,102			2,326			2,255
Acquired asset depreciation & amortization		1,338			1,398			2,676			2,798
Other operating expenses (1)		271			-			1,335			-
Other adjustments		-			367			-			4
Loss on equity securities		280			1,581			1,593			1,581
Income taxes		(36	)		(1,776	)		591			(2,115	)
Adjusted net income		204			1,692			900			4,165
Depreciation & amortization		464			328			907			649
Interest and other expense, net		929			1,222			1,822			2,258
Adjusted income taxes (2)		(317	)		658			(734	)		1,582
Adjusted EBITDA	$	1,280		$	3,900		$	2,895		$	8,654
Adjusted EBITDA margin		5.5	%		13.6	%		6.1	%		14.7	%


Diluted loss per share (GAAP)	$	(0.07	)	$	(0.02	)	$	(0.18	)	$	(0.01	)

Diluted adjusted earnings per share	$	0.00		$	0.04		$	0.02		$	0.09
Weighted-average common shares:
Diluted GAAP		43,486			42,354			43,443			42,204
Diluted Adjusted		44,450			44,656			44,516			44,020

(1) Other operating expenses for the three months ended June 30, 2024 includes a credit of $(0.1) million related to an unclaimed property audit and $0.4 million of restructuring-related charges. Other operating expenses for the six months ended June 30, 2024 includes a $0.5 million commission fee paid in connection with the receipt of employee retention credits, a loss of $0.3 million related to an unclaimed property audit, and $0.4 million of restructuring-related charges.

(2) Adjusted income taxes includes the tax effect of adjusting for the reconciling items using the tax rates in the jurisdictions in which the reconciling items arise.

Company Contact:		Investors Contact:
Jennifer Cote		Three Part Advisors
Chief Financial Officer		Sandy Martin
(508) 893-3120		HBIO@threepa.com
		(214) 616-2207

	June 30, 2024			December 31, 2023
Debt, including unamortized deferred financing costs	$	35,680		$	36,563
Unamortized deferred financing costs		420			560
Cash and cash equivalents		(4,048	)		(4,283	)
Net debt	$	32,052		$	32,840

Financial Results Summary	Three Months Ended June 30,						Six Months Ended June 30,
(unaudited, $ in millions except per share data)	2024			2023			2024			2023
Revenues	$	23.1		$	28.8		$	47.6		$	58.7
Gross margin		57.2	%		58.0	%		58.8	%		59.6	%
Operating (loss) income (GAAP)	$	(2.1	)	$	0.8		$	(4.3	)	$	2.5
Adjusted operating income	$	0.8		$	3.6		$	2.0		$	8.0
Net loss (GAAP)	$	(2.9	)	$	(1.0	)	$	(7.6	)	$	(0.4	)
Diluted loss per share (GAAP)	$	(0.07	)	$	(0.02	)	$	(0.18	)	$	(0.01	)
Diluted adjusted (loss) earnings per share	$	0.00		$	0.04		$	0.02		$	0.09
Adjusted EBITDA	$	1.3		$	3.9		$	2.9		$	8.7
Adjusted EBITDA margin		5.5	%		13.6	%		6.1	%		14.7	%
Cash flow provided by operations							$	0.6		$	5.4